LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Zoledronsyra Evolan
(zoledronic acid)

Asp no: 2013-0129

This module reflects the scientific discussion for the approval of Zoledronsyra Evolan. The procedure was finalised at 2014-01-16. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se

I. INTRODUCTION

The application for Zoledronsyra Evolan, 4 mg/5 ml, concentrate for infusion, is a generic application made according to Article 10(1) of Directive 2001/83/EC. The applicant, Evolan Pharma AB applies through the Swedish National Procedure.

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Zometa, 4 mg powder and solvent for solution for infusion authorised in Community since 2001, with Novartis Europharm Ltd as marketing authorisation holder.

For approved indications, see the Summary of Product Characteristics.

II. QUALITY ASPECTS

II.1 Introduction

Zoledronsyra Evolan is presented in the form of concentrate for infusion containing 0.8 mg per ml mg of Zoledronic acid (monohydrate). The excipients are mannitol, sodium citrate and water for injection. The product is packed in a plastic vial or in a glass vial.

II.2 Drug Substance

Zoledronic acid does not have a monograph in the Ph Eur.
The active ingredient Zoledronic acid is a white to off white powder. Freely soluble in 1N Sodium hydroxide. Zoledronic acid exhibits polymorphism which is monohydrate. The molecule of Zoledronic Acid does not exhibit any isomerism.
The route of synthesis has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The active substance specification includes relevant tests and the limits for impurities/degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies under ICH conditions have been conducted and the data provided are sufficient to confirm the retest period.

II.3 Medicinal Product

Zoledronsyra Evolan concentrate for infusion is formulated using excipients described in the current Ph Eur. The excipients used are not of human and animal origin.

The product development has taken into consideration the physico-chemical characteristics of the active substance, such as aqueous solubility, polymorphism, and stability.

The manufacturing process has been sufficiently described and critical steps identified. Results from the process validation studies confirm that the process is under control and ensure both batch to batch reproducibility and compliance with the product specification.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies under ICH conditions have been performed and data presented support the shelf life claimed in the SPC, with no special storage precautions.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

The applied product is to be administered as an aqueous intravenous solution containing the same active substance as the currently authorised product. None of the excipients are known to interact with the drug substance. For this type of product, no bioequivalence studies are required according to the Guideline on the investigation of Bioequivalence (CHMP/QWP/EWP/1401/98 Rev. 1).

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

User consultation
A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to Zometa EMEA/H/C/336/X/02 (for content) and Hydroklortiazid Evolan 111:2009/6024-6026 (for layout and design). The bridging report submitted by the applicant has been found acceptable.

The risk/benefit ratio is considered positive and Zoledronsyra Evolan, 4 mg/5 ml, concentrate for infusion, is recommended for approval.

VI. APPROVAL

Zoledronsyra Evolan, 4 mg/5 ml, concentrate for infusion, was approved in the national procedure on 20140116.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Scope	Procedure number	Product Information affected	Date of start of the procedure	Date of end of procedure	Approval/ non approval	Assessment report attached
						Y/N (version)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se